|
Index of reports
> Cases with White Blood Cell Count Decreased ()
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Thalomid (Thalidomide) where reactions include white blood cell count decreased. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Thalomid side effects in male
Reported by a physician from United States on 2012-04-27
Patient: male, weighing 158.9 kg (349.6 pounds)
Reactions: White Blood Cell Count Decreased, Basal Cell Carcinoma, Febrile Neutropenia, Squamous Cell Carcinoma of Skin, Thrombocytopenia
Adverse event resulted in: hospitalization
Drug(s) suspected as cause:
Revlimid
Administration route: Oral
Start date: 2011-11-01
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2008-01-01
End date: 2008-07-18
Melphalan Hydrochloride
Start date: 2006-01-01
End date: 2007-01-01
Melphalan Hydrochloride
Dosage: 2 milligram
Start date: 2011-04-08
Melphalan Hydrochloride
End date: 2011-11-21
Thalomid
Dosage: dose increased
Start date: 2006-01-01
End date: 2007-01-01
Thalomid
Indication: Multiple Myeloma
Start date: 2004-01-01
End date: 2005-01-01
Revlimid
Dosage: 15 milligram
Administration route: Oral
Start date: 2011-04-08
End date: 2012-01-12
Revlimid
Dosage: 10 milligram
Administration route: Oral
Start date: 2011-07-01
Revlimid
Administration route: Oral
Start date: 2008-07-18
Thalomid
Start date: 2007-01-01
End date: 2008-01-01
Other drugs received by patient: Metoclopramide; Clopidogrel; Lovastatin; Zometa; Rocephin; Filgrastim; Lisinopril and Hydrochlorothiazide; Atenolol; Zolpidem; Mupirocin; Neupogen; Warfarin Sodium; Plavix; Hydrocodone Bitartrate + Acetaminophen; Aspirin; Neupogen; Prednisone TAB; Solu-Medrol; Sodium Chloride; Kenalog
Possible Thalomid side effects in male
Reported by a physician from United States on 2012-04-03
Patient: male, weighing 158.9 kg (349.6 pounds)
Reactions: White Blood Cell Count Decreased, Basal Cell Carcinoma, Squamous Cell Carcinoma of Skin, Thrombocytopenia
Drug(s) suspected as cause:
Revlimid
Dosage: 5 milligram
Administration route: Oral
Start date: 2011-11-01
End date: 2012-01-01
Melphalan Hydrochloride
Dosage: 2 milligram
Start date: 2011-04-08
Revlimid
Dosage: 10 milligram
Administration route: Oral
Start date: 2011-07-01
Thalomid
Indication: Multiple Myeloma
Start date: 2004-01-01
End date: 2005-01-01
Thalomid
Dosage: dose increased
Start date: 2006-01-01
End date: 2007-01-01
Thalomid
Start date: 2007-01-01
End date: 2008-01-01
Melphalan Hydrochloride
End date: 2011-11-21
Revlimid
Dosage: 25 milligram
Administration route: Oral
Indication: Multiple Myeloma
Start date: 2008-01-01
Revlimid
Dosage: 15 milligram
Administration route: Oral
Start date: 2011-04-08
Melphalan Hydrochloride
Start date: 2006-01-01
End date: 2007-01-01
Other drugs received by patient: Filgrastim; Lovastatin; Metoclopramide; Zometa; Rocephin; Atenolol; Aspirin; Prednisone TAB; Solu-Medrol; Lisinopril and Hydrochlorothiazide; Neupogen; Clopidogrel; Zolpidem; Hydrocodone Bitartrate and Acetaminophen; Warfarin Sodium; Sodium Chloride; Mupirocin; Neupogen; Kenalog
Possible Thalomid side effects in female
Reported by a physician from United States on 2011-12-30
Patient: female
Reactions: White Blood Cell Count Decreased, Intestinal Ischaemia, Septic Shock, Tremor, Paraesthesia
Adverse event resulted in: death
Drug(s) suspected as cause:
Thalomid
|
